ArriVent BioPharma Inc.
Organization details
- Legal name
- ArriVent BioPharma Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Newtown Square
- Headquarters state / province
- Pennsylvania
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AVBP
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001868279
Board of directors
-
Bahija Jallal · DirectorSince 2024
- Since 2024
-
Chris Nolet · DirectorSince 2024
- Since 2024
-
John Hohneker · DirectorSince 2024
-
Kristine Peterson · DirectorSince 2024
-
Merdad Parsey · DirectorSince 2025
-
Stuart Lutzker · Director · President of R&DSince 2024
-
Zhengbin Yao · Director · President and CEOSince 2024
Chief executives
Director election results
Annual meeting of June 18, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
61.0%
-
94.8%
-
99.7%
Board connections
8 of this board's directors also sit on 22 other boards. 21 are in the same sector.
-
Immunocore Holdings plc Same sectorvia Bahija Jallal and Kristine Peterson
-
ADARx Pharmaceuticals Inc. Same sectorvia Carl L. Gordon
-
Adicet Bio Inc. Same sectorvia Carl L. Gordon
-
Alumis Inc. Same sectorvia Zhengbin Yao
-
Ardelyx Inc. Same sectorvia Merdad Parsey
-
BioAge Labs Inc. Same sectorvia James Healy
-
BlossomHill Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Bolt Biotherapeutics Inc. Same sectorvia James Healy
-
Compass Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Curis Inc. Same sectorvia John Hohneker
-
Electra Therapeutics Inc. Same sectorvia Carl L. Gordon
- via Bahija Jallal
-
Enanta Pharmaceuticals Inc. Same sectorvia Kristine Peterson
-
Jasper Therapeutics Inc. Same sectorvia Chris Nolet
-
Keros Therapeutics Inc. Same sectorvia Carl L. Gordon
-
MBX Biosciences Inc. Same sectorvia Carl L. Gordon
-
Mineralys Therapeutics Inc. Same sectorvia Kristine Peterson
-
Natera Inc. Same sectorvia James Healy
-
Rapport Therapeutics Inc. Same sectorvia James Healy
-
Sagimet Biosciences Inc. Same sectorvia Merdad Parsey
-
Scribe Therapeutics Inc. Same sectorvia Carl L. Gordon
-
Seaport Therapeutics Inc. Same sectorvia James Healy
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $12,983,320
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 30, 2026 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +16,265 | $3.65 | $59,374 |
| Oct 30, 2026 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +410 | $2.28 | $935 |
| Oct 30, 2026 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +4,550 | $2.28 | $10,381 |
| Oct 30, 2026 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +1,820 | $2.28 | $4,152 |
| Oct 30, 2026 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +17,648 | $6.24 | $110,055 |
| Dec 10, 2025 | HHLR ADVISORS, LTD. 10% owner | Open-market sale | −555,555 | $23.37 | $12,983,320 |
| Jul 11, 2025 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,050 | $2.28 | $4,674 |
| Jul 11, 2025 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,600 | $2.28 | $5,928 |
| Jul 11, 2025 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +6,503 | $2.28 | $14,827 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,700 | $6.24 | $16,848 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,867 | $2.28 | $6,537 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +7,164 | $2.28 | $16,334 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +2,471 | $2.28 | $5,634 |
| Sep 19, 2024 | LaChapelle Robin Officer (Chief Operating Officer) | Option exercise | +12,364 | $3.65 | $45,129 |
| Jan 30, 2024 | HHLR ADVISORS, LTD. 10% owner | Derivative conversion | +3,616,041 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about ArriVent BioPharma Inc.
Who is the CEO of ArriVent BioPharma Inc.?
Zhengbin Yao has been ArriVent BioPharma Inc.'s President and CEO since January 2024.
How many directors are on ArriVent BioPharma Inc.'s board?
ArriVent BioPharma Inc.'s board has 9 directors: Bahija Jallal, Carl L. Gordon, Chris Nolet, James Healy, John Hohneker, Kristine Peterson, Merdad Parsey, Stuart Lutzker and Zhengbin Yao.
Are ArriVent BioPharma Inc. insiders buying or selling shares?
Over the last 12 months, ArriVent BioPharma Inc. insiders made no open-market purchases and sold $13.0 million of shares in 1 sale on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="arrivent-biopharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.